Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance.

Wang, Yulei; Lu, Li-Chun; Guan, Yinghui; Ho, Ming-Chih; Lu, Shan; Spahn, Jessica; Hsu, Chih-Hung

Wang, Yulei; Lu, Li-Chun; Guan, Yinghui; Ho, Ming-Chih; Lu, Shan; Spahn, Jessica; Hsu, Chih-Hung.

Afiliación

Wang Y; Oncology Biomarker Development, Genentech, South San Francisco, USA.
Lu LC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Guan Y; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
Ho MC; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Lu S; Oncology Biomarker Development, Genentech, South San Francisco, USA.
Spahn J; Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Hsu CH; Oncology Biomarker Development, Genentech, South San Francisco, USA.

Exp Hematol Oncol ; 10(1): 45, 2021 Aug 16.

Article en En | MEDLINE | ID: mdl-34399826

Palabras clave

Atezolizumab; Bevacizumab; Hepatocellular carcinoma; Immune exclusion; PD-L1

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Exp Hematol Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google